KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Receivables (2016 - 2025)

Nektar Therapeutics has reported Receivables over the past 16 years, most recently at $1.0 million for Q4 2025.

  • Quarterly results put Receivables at $1.0 million for Q4 2025, down 9.09% from a year ago — trailing twelve months through Dec 2025 was $1.0 million (down 9.09% YoY), and the annual figure for FY2025 was $1.0 million, down 9.09%.
  • Receivables for Q4 2025 was $1.0 million at Nektar Therapeutics, up from $200000.0 in the prior quarter.
  • Over the last five years, Receivables for NKTR hit a ceiling of $30.2 million in Q1 2022 and a floor of $200000.0 in Q3 2025.
  • Median Receivables over the past 5 years was $3.6 million (2024), compared with a mean of $10.9 million.
  • Biggest five-year swings in Receivables: crashed 90.09% in 2023 and later increased 20.77% in 2024.
  • Nektar Therapeutics' Receivables stood at $23.9 million in 2021, then tumbled by 72.04% to $6.7 million in 2022, then plummeted by 74.48% to $1.7 million in 2023, then tumbled by 35.48% to $1.1 million in 2024, then fell by 9.09% to $1.0 million in 2025.
  • The last three reported values for Receivables were $1.0 million (Q4 2025), $200000.0 (Q3 2025), and $1.1 million (Q4 2024) per Business Quant data.